Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers.

Clicks: 396
ID: 57803
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #8 of 20 articles by views in neurobiology of aging

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Our aim was to investigate the patterns and trajectories of white matter (WM) diffusion abnormalities in microtubule-associated protein tau (MAPT) mutations carriers. We studied 22 MAPT mutation carriers (12 asymptomatic, 10 symptomatic) and 20 noncarriers from 8 families, who underwent diffusion tensor imaging (DTI) and a subset (10 asymptomatic, 6 symptomatic MAPT mutation carriers, and 10 noncarriers) were followed annually (median = 4 years). Cross-sectional and longitudinal changes in mean diffusivity (MD) and fractional anisotropy were analyzed. Asymptomatic MAPT mutation carriers had higher MD in entorhinal WM, which propagated to the limbic tracts and frontotemporal projections in the symptomatic stage compared with noncarriers. Reduced fractional anisotropy and increased MD in the entorhinal WM were associated with the proximity to estimated and actual age of symptom onset. The annualized change of entorhinal MD on serial DTI was accelerated in MAPT mutation carriers compared with noncarriers. Entorhinal WM diffusion abnormalities precede the symptom onset and track with disease progression in MAPT mutation carriers. Our cross-sectional and longitudinal data showed a potential clinical utility for DTI to track neurodegenerative disease progression for MAPT mutation carriers in clinical trials.
Reference Key
chen2019trackingneurobiology Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Chen, Qin;Boeve, Bradley F;Schwarz, Christopher G;Reid, Robert;Tosakulwong, Nirubol;Lesnick, Timothy G;Bove, Jessica;Brannelly, Patrick;Brushaber, Danielle;Coppola, Giovanni;Dheel, Christina;Dickerson, Bradford C;Dickinson, Susan;Faber, Kelley;Fields, Julie;Fong, Jamie;Foroud, Tatiana;Forsberg, Leah;Gavrilova, Ralitza H;Gearhart, Debra;Ghoshal, Nupur;Goldman, Jill;Graff-Radford, Jonathan;Graff-Radford, Neill R;Grossman, Murray;Haley, Dana;Heuer, Hilary W;Hsiung, Ging-Yuek R;Huey, Edward;Irwin, David J;Jack, Clifford R;Jones, David T;Jones, Lynne;Karydas, Anna M;Knopman, David S;Kornak, John;Kramer, Joel;Kremers, Walter;Kukull, Walter A;Lapid, Maria;Lucente, Diane;Lungu, Codrin;Mackenzie, Ian R A;Manoochehri, Masood;McGinnis, Scott;Miller, Bruce L;Pearlman, Rodney;Petrucelli, Leonard;Potter, Madeline;Rademakers, Rosa;Ramos, Eliana M;Rankin, Katherine P;Rascovsky, Katya;Sengdy, Pheth;Shaw, Leslie;Syrjanen, Jeremy;Tatton, Nadine;Taylor, Joanne;Toga, Arthur W;Trojanowski, John;Weintraub, Sandra;Wong, Bonnie;Boxer, Adam L;Rosen, Howie;Wszolek, Zbigniew;Kantarci, Kejal;, ;
Journal neurobiology of aging
Year 2019
DOI
S0197-4580(19)30289-1
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.